InnoCan Pharma (INNO) Stock Overview
A pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
INNO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
InnoCan Pharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$9.47 |
| 52 Week High | CA$21.00 |
| 52 Week Low | CA$6.01 |
| Beta | -0.060 |
| 1 Month Change | 41.34% |
| 3 Month Change | -48.81% |
| 1 Year Change | -8.94% |
| 3 Year Change | -51.44% |
| 5 Year Change | -70.27% |
| Change since IPO | -41.72% |
Recent News & Updates
It's Down 26% But InnoCan Pharma Corporation (CSE:INNO) Could Be Riskier Than It Looks
Jan 10
InnoCan Pharma Corporation (CSE:INNO) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing
Nov 26Revenues Tell The Story For InnoCan Pharma Corporation (CSE:INNO) As Its Stock Soars 42%
Sep 30Recent updates
It's Down 26% But InnoCan Pharma Corporation (CSE:INNO) Could Be Riskier Than It Looks
Jan 10InnoCan Pharma Corporation (CSE:INNO) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing
Nov 26Revenues Tell The Story For InnoCan Pharma Corporation (CSE:INNO) As Its Stock Soars 42%
Sep 30Why Investors Shouldn't Be Surprised By InnoCan Pharma Corporation's (CSE:INNO) 32% Share Price Surge
Jul 02InnoCan Pharma Corporation's (CSE:INNO) P/S Is Still On The Mark Following 29% Share Price Bounce
Feb 23We're Hopeful That InnoCan Pharma (CSE:INNO) Will Use Its Cash Wisely
Aug 09It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year
May 04Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?
Dec 06We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth
Aug 15Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth
Apr 19Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?
Jul 20We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully
Apr 05Shareholder Returns
| INNO | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 35.3% | -13.3% | -3.8% |
| 1Y | -8.9% | 4.8% | 26.8% |
Return vs Industry: INNO underperformed the Canadian Pharmaceuticals industry which returned 3.9% over the past year.
Return vs Market: INNO underperformed the Canadian Market which returned 28.4% over the past year.
Price Volatility
| INNO volatility | |
|---|---|
| INNO Average Weekly Movement | 20.6% |
| Pharmaceuticals Industry Average Movement | 13.9% |
| Market Average Movement | 10.6% |
| 10% most volatile stocks in CA Market | 20.2% |
| 10% least volatile stocks in CA Market | 3.4% |
Stable Share Price: INNO's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: INNO's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Iris Bincovich | innocanpharma.com |
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management.
InnoCan Pharma Corporation Fundamentals Summary
| INNO fundamental statistics | |
|---|---|
| Market cap | CA$44.76m |
| Earnings (TTM) | -CA$4.40m |
| Revenue (TTM) | CA$36.80m |
Is INNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INNO income statement (TTM) | |
|---|---|
| Revenue | US$27.03m |
| Cost of Revenue | US$3.12m |
| Gross Profit | US$23.91m |
| Other Expenses | US$27.14m |
| Earnings | -US$3.23m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 88.47% |
| Net Profit Margin | -11.96% |
| Debt/Equity Ratio | 23.0% |
How did INNO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/30 07:23 |
| End of Day Share Price | 2026/01/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
InnoCan Pharma Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.